Antimuscarinics and Cognitive Function

European Urology

Volumn 50, Issue 2, 2006, Pages 211-212

  De Ridder, Dirk ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DARIFENACIN; MUSCARINIC M1 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; COGNITION; COGNITIVE DEFECT; COMORBIDITY; DEMENTIA; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SELECTIVITY; EDITORIAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LIVER BLOOD FLOW; OVERACTIVE BLADDER; PRIORITY JOURNAL; SLEEP DISORDER;

AGED; COGNITION DISORDERS; HUMANS; MUSCARINIC ANTAGONISTS; URINARY BLADDER, OVERACTIVE;

EID: 33745853516     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.03.060     Document Type: Editorial

References (10)

1. Callaway E., Halliday R., and Naylor H. Cholinergic activity and constraints on information-processing. Biol Psychol 33 (1992) 1-22
2. Gray S.L., Lai K.V., and Larson E.B. Drug-induced cognition disorders in the elderly- incidence, prevention and management. Drug Saf 21 (1999) 101-122
3. Staskin D.R. Overactive bladder in the elderly-a guide to pharmacological management. Drugs Aging 22 (2005) 1013-1028
4. Scheife R., and Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 27 (2005) 144-153
5. Ancelin M.L., Artero S., Portet F., et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 332 (2006) 455-458
6. Jewart R.D., Green J., Lu C.J., et al. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am J Geriatr Psychiatry 13 (2005) 324-328
7. Mori K., Yamashita H., Nagao M., et al. Effects of anticholinergic drug withdrawal on memory, regional cerebral blood flow and extra-pyramidal side-effects in schizophrenic patients. Pharmacopsychiatry 35 (2002) 6-11
8. Nagels G., De Deyn P.P., Vleugels L., et al. A prospective randomised double-blind cross-over dose-titration study to evaluate the cognitive safety profile of tolterodine as compared to oxybutynin in multiple sclerosis patients with a neurogenic overactive bladder: a planned interim analysis. Mult Scler 10 (2004) S152
9. Womack K.B., and Heilman K.M. Tolterodine and memory-dry but forgetful. Arch Neurol 60 (2003) 771-773
10. Kay G., Crook T., Rekeda L., et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol. 50 (2006) 317-326